DORA PCCTC Trial Videos

The Transformative Development and Progress of The Prostate Cancer Clinical Trials Consortium - Howard Scher, Michael Morris, and Jake Vinson

Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer. The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to criti...

Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz

Alicia Morgans welcomes Michael Morris and Lawrence Schwartz to discuss the Prostate Cancer Working Group criteria as a refresher for investigators who are treating men with prostate cancer in clinical trials. Biographies: Michael J. Morris, MD., is the Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Ketteri...

The DORA Trial, Comparing Overall Survival in Patients Treated with Docetaxel vs. Docetaxel plus Radium-223 - Michael Morris

Michael Morris, Professor of Medicine and GU Medical Oncologist, Memorial Sloan Kettering Cancer Center joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to discuss the DORA trial. Michael Morris is The DORA trial principal investigator for this Prostate Cancer Clinical Trials Consortium (PCCTC) trial. The primary objective of this study is to compare...
email news signup